Navigation Links
Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results
Date:5/13/2010

-------------- 13,762 19,553 ------------------------------------------------------------------------- Loss from operations (7,340) (13,442) ------------------------------------------------------------------------- Other income Interest income 58 154 Foreign exchange gain 1,402 900 ------------------------------------------------------------------------- 1,460 1,054 ------------------------------------------------------------------------- Net loss for the period (5,880) (12,388) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Net loss per share Basic and diluted (0.09) (0.23) ------------------------------------------------------------------------- ------------------------------------------------------------------------- Weighted average number of shares Basic and diluted 63,089,954 53,187,470 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Interim Consolidated Balance Sheet Information (in thousands) (unaudited) ------------------------------------------------------------------------- As at As at March 31, December 31, 2010 2009 ------------------------------------------------------------------------- ----------------------------
'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
2. Aeterna Zentaris Receives Orphan-Drug Designation from the FDA for AEZS-108 in Ovarian Cancer
3. AEterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
4. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
5. AEterna Zentaris Announces Appointment of New Board Member
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. AEterna Zentaris Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
9. AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
10. AEterna Zentaris Receives US$5.5 Million from Institutional Investors
11. AEterna Zentaris to Raise US$5.5 Million from Institutional Investors at US$1.20 Per Share
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)... 22, 2015  Derma Sciences, Inc. (Nasdaq: ... advanced wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, ... added to the Premier, Inc. Regenerative Skin Grafting ... the AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue ...
(Date:12/24/2014)... BOTHELL, Wash. , Dec. 24, 2014   BioLife Solutions ... manufacturer and marketer of proprietary clinical grade hypothermic storage ... thermal shipping products for cells and tissues  ("BioLife" or ... Annual Meeting of Stockholders on May 4, 2015 (the "Annual ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
Breaking Biology Technology:Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5BioLife Solutions Sets Date for Annual Meeting of Stockholders 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2
... Conferences in ... October ... OREX ), a biopharmaceutical company focused on the treatment,of obesity and ... for October 2008, which includes,six data presentations and one sponsored symposium ...
... Germany, Sept. 29 Nomad Bioscience GmbH,announces ... agreement with Bayer,Innovation GmbH and Icon Genetics ... technology platforms, including its transient expression,technology magnICON(R), ... in green plants. The agreement provides,Nomad with ...
... Cooperation with Kentucky Bioprocessing for future-oriented technology, ... 29 Bayer,Innovation GmbH and Kentucky Bioprocessing, ... at KBP,s Owensboro plant in the US ... biopharmaceuticals. Based on Bayer,s proprietary,magnICON(R) technology, plant ...
Cached Biology Technology:Orexigen Therapeutics Announces Multiple Data Presentations at The Obesity Society Annual Scientific Meeting 2Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 2Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 3Bayer Broadens Its Manufacturing Basis for Biopharmaceuticals in Tobacco Plants 4
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
(Date:12/11/2014)... , Dec. 10, 2014  That blood pressure plays a role ... Hypertension – the medical term for high blood pressure – ... and the inflatable cuff that,s used in measuring blood pressure ... there,s nothing new about hypertension, its triggers and its effects. ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ...
Breaking Biology News(10 mins):Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... harness the energy of ATP (or GTP, a related ... examples of motors include myosin and dynein, proteins that ... of actin or tubulin proteins. The ATP-dependent assembly of ... motor: for instance, the march of white blood cells ...
... Bork, Ph.D., Senior Bioinformatics Scientist at the European Molecular ... that they have identified a new primate-specific gene family ... of eight family members, the RGP gene cluster may ... primates from the rest of the animal kingdom. , ...
... scientists has,found the first clear evidence that the ... recognize and respond to a million,different proteins might ... apparent function is to jump around in genetic ... the genetic material, and scientists,have suspected that this ...
Cached Biology News:DNA Recombination and Repair—A New Twist to RecA Function 2Scientists document complex genomic events leading to the birth of new genes 2Scientists document complex genomic events leading to the birth of new genes 3Jumping gene helps explain immune system's abilities 2Jumping gene helps explain immune system's abilities 3
... pLivSelect is a ... for recombinant identification. Recombinant ... colony survival, eliminating the ... screening. This quick and ...
... does for enzyme-/substrate-based blotting what intensifying screens do ... up to 10-fold (or one order of magnitude) ... Signal Enhancer membrane treatment is a simple, 15-minute ... current Western blotting protocol. The result is an ...
... a multi-functional program that searches ... a sequence file for polymerase ... site-directed mutagenesis, and various hybridization ... and secondary structure of oligonucleotides ...
...
Biology Products: